Physician profile
Albert M Morier
NPI 1285670018
$346,809.43
in general payments reported to CMS, 2019-2025
14 companies · $31K in 2025
The $31K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107K · 2020: $29K · 2021: $48K · 2022: $43K · 2023: $43K · 2024: $47K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $106K · Travel and Lodging: $12K · Food and Beverage: $1,514 · Consulting Fee: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $105,986.00 |
| Travel and Lodging | $12,348.60 |
| Food and Beverage | $1,514.11 |
| Consulting Fee | $1,032.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $340,715.54 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $4,000.00 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $1,013.06 | 2023-2025 | Miebo, Infuse, Biotrue |
| Amgen INC. | $318.31 | 2024-2025 | Tepezza |
| Coopervision INC. | $173.32 | 2019-2025 | Misight Contact Lens, Myday Contact Lens |
| Alcon Vision LLC | $153.59 | 2023-2025 | Total30, Precision7 |
| Astellas Pharma US INC | $132.30 | 2024 | Izervay |
| Spark Therapeutics, INC. | $91.82 | 2019 | |
| Lkc Technologies, INC. | $66.77 | 2022 | |
| Maculogix, INC. | $62.39 | 2019-2020 | |
| Abb Con-Cise Optical Group LLC | $27.88 | 2021 | |
| Aerie Pharmaceuticals, INC. | $22.02 | 2019 | |
| Carl Zeiss Meditec, INC. | $18.47 | 2019 | |
| Kala Pharmaceuticals, INC. | $13.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Morier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.